Pembrolizumab-Induced Thyroiditis
- PMID: 33852471
- DOI: 10.1097/MJT.0000000000001367
Pembrolizumab-Induced Thyroiditis
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Kwok G, Yau TC, Chiu JW, et al. Pembrolizumab (keytruda) . Hum Vaccin Immunother. 2016;12:2777–2789.
-
- Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors . Rev Endocr Metab Disord. 2018;19:325–333.
-
- Aschenbrenner DS, New esophageal cancer indication for pembrolizumab . Am J Nurs. 2019;119:21.
-
- Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies . Nat Rev Endocrinol. 2017;13:195–207.
-
- Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis . JAMA Oncol. 2018;4:173–182.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources